Christie J. Hilton, DO

Christie J. Hilton, DO, discusses the first-line standard of care and changes in the second-line SOC, including key findings from the phase 3 DESTINY-Breast03 trial, in patients with HER2-positive metastatic breast cancer.

Christie J. Hilton, DO, discusses the potential impact of the ongoing phase 2 CompassHER2-pCR trial for patients with HER2-positive breast cancer.

Christie J. Hilton, DO, discusses the impact of trastuzumab deruxtecan on the treatment of patients with HER2-positive metastatic breast cancer and ongoing research with the agent in this patient population.

The QOPI program creates a uniform measurement of the quality of care delivered by an oncologist; this affords self-examination and directed improvement of practices.